Physician profile
Alan Dresner
NPI 1316911654
$62,753.02
in general payments reported to CMS, 2019-2025
62 companies · $4,030 in 2025
The $4,030 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $11K · 2021: $16K · 2022: $5,580 · 2023: $4,051 · 2024: $4,214 · 2025: $4,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,457 · Education: $89.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,747.82 |
| Consulting Fee | $1,457.00 |
| Education | $89.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $20,517.21 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $14,511.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $5,008.52 | 2019-2020 | |
| Novo Nordisk INC | $2,916.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,877.12 | 2019-2025 | Korlym |
| Lilly USA, LLC | $1,834.74 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,762.99 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $1,651.87 | 2019-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $1,203.42 | 2019-2025 | Afrezza |
| Radius Health, INC. | $1,123.76 | 2019-2025 | Tymlos |
| Abbvie INC. | $950.72 | 2019-2025 | Synthroid, Botox |
| Roche Diabetes Care, INC. | $777.00 | 2024 | |
| Xeris Pharmaceuticals, INC. | $640.34 | 2021-2025 | Recorlev |
| Insulet Corporation | $600.89 | 2019-2025 | Omnipod |
| Novo Nordisk As | $580.00 | 2023 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $456.34 | 2019-2022 | |
| Abbott Laboratories | $444.07 | 2019-2025 | Freestyle Libre |
| Medtronic, INC. | $441.70 | 2021-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $427.28 | 2019-2023 | Steglatro |
| Beta Bionics, INC. | $394.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $380.52 | 2021-2025 | Isturisa, Signifor Lar |
| Amneal Pharmaceuticals LLC | $367.62 | 2019-2025 | Unithroid |
| Genzyme Corporation | $272.00 | 2019-2020 | |
| Ibsa Pharma INC. | $254.56 | 2019-2023 | Tirosint, Licart |
| Pfizer INC. | $246.00 | 2019-2024 | |
| Antares Pharma, INC. | $238.73 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Endo Pharmaceuticals INC. | $234.47 | 2019-2022 | |
| Dexcom, INC. | $229.05 | 2019-2024 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $199.67 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $172.88 | 2020-2024 | Crysvita |
| Alvogen INC | $166.03 | 2023-2024 | Teriparatide |
| Horizon Therapeutics Plc | $164.74 | 2021-2023 | Tepezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.06 | 2019-2023 | Cycloset |
| Ascendis Pharma Endocrinology INC | $127.15 | 2023-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $117.54 | 2021-2024 | Strensiq |
| Becton, Dickinson and Company | $114.39 | 2019-2022 | |
| Sentynl Therapeutics, INC. | $100.00 | 2023 | |
| Acerus Pharmaceuticals Corporation | $97.64 | 2021 | |
| Verity Pharmaceuticals INC. | $78.74 | 2024-2025 | Tlando |
| Embecta Corp. | $77.19 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sekisui Diagnostics LLC | $75.00 | 2022 | |
| Kyowa Kirin, INC. | $74.19 | 2024 | Crysvita |
| Tandem Diabetes Care, INC. | $68.07 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $64.13 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $56.56 | 2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $51.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $42.57 | 2025 | Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $41.16 | 2021-2022 | |
| Clarus Therapeutics INC. | $40.13 | 2021 | |
| Averitas Pharma INC. | $37.16 | 2023 | Qutenza |
| Medtronic Minimed, INC. | $36.77 | 2019 | |
| Eusa Pharma (US) LLC | $36.10 | 2022 | |
| Amryt Pharma Holdings Ltd | $27.71 | 2023 | Mycapssa |
| Kowa Pharmaceuticals America, INC. | $26.72 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.20 | 2019 | |
| Esperion Therapeutics, INC. | $24.97 | 2020 | |
| Neurocrine Biosciences, INC. | $21.87 | 2025 | |
| Ascend Therapeutics US, LLC | $21.32 | 2021 | |
| Tolmar, INC. | $19.00 | 2025 | Jatenzo |
| Aytu Biopharma, INC. | $15.31 | 2020 | |
| Valeritas, INC. | $13.55 | 2019 | |
| Lifescan, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Dresner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.